1De The Hugues , Lavau C, Marchio A, et al. The PML- RARafusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell, 1991,66 (4) : 675 - 684.
2Kakizuka A, Miller WH, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell, 1991,66(4) :663 -674.
3Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic Leukemia with tretinoin ( all - trans - retinoic acid). N Engl J Med, 1991,324 (20) : 1385 - 1393.
4Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood, 2000,95 (1) :90 -95.
5De Botton S, Chevret S, Coiteux V, et al. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia, 2003,17 (2) : 339 - 342.
6Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid ( ATRA ) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood, 1999,94 (4) : 1192 - 1200.
7Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with alhrans - retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood, 2004, 103 (4) : 1237 - 1243.
8Frankel SR, Eardley A, Lauwers G, et al. The " retinoic acid syndrome" in acute promyelocytic leukemia. Ann. Intern Med, 1992,117 (4) : 292 - 296.
9De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans - retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood, 1998,92 (8) :2712 - 2718.
10Tallman MS, Andersen JW, Schiffer CA, et al. All - trans retinoic acid in acute promyelocytic leukemia: long - term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood, 2002, 100 ( 13 ) : 4298 -4302.
二级参考文献12
1Hsu H C,Tsai W H,Chen P G,et al. In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemic cells[J]. Eur J Haematol, 1999, 63(1): 11-18.
2Borowitz M J, Guenther K L, Shults K E, et al. Immunophenotyping of acute leukemia by flow cytometric analysis use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color-analysis[J]. Am J Clin Pathol, 1993, 100(5): 534-540.
3Astudillo L, Loche F, Reynish W, et al. Sweet's syndrome associated with retinoic acid syndrome in a patient with promyelocytic leukemia[J]. Ann Hematol, 2002, 81(2): 111-114.
4Varghese L, Janckila A, Yam L T. Acute promyelocytic leukemia. New methods in diagnosis and treatment[J]. J Ky Med Assoc, 1999, 97(2): 61-65.
5Read R A, Moore E E, Moore F A, et al. Lipopolysaccharide-induced CD11B-mediated neutrophil-endothelial adhesion is not required for polymorphonuclear cell priming[J]. J Trauma, 1994, 37(1): 13-17.
6Paietta E, Andersen J, Gallagher R, et al. The immunophenotyping of acute promyelocytic leukemia(APL): an ECOg study[J]. Leukemia, 1994, 8(7): 1108-1112.
7Laurent T, Markert M, Von Fliedner V, et al. CD11b/CD18 expression, adherence, and chemotaxis of granulocyte in adult respiratory distress syndrome[J]. Am J Respir Crit Care Med, 1994,149(6): 1534-1538.
